Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Today 8:00 EDT

Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup ↗

October 01, 2026

Via Chartmill

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

September 30, 2026

Built on substance, not hype, Teva's mega rally is just getting started.

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ↗

September 29, 2026

Via The Motley Fool

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

September 28, 2026

Teva Releases Q3 2026 Aide Memoire

September 23, 2026

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

September 23, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard...

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings ↗

September 23, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company...

Topics Bankruptcy

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline ↗

September 22, 2026

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

September 18, 2026

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

September 18, 2026

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

September 18, 2026

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

September 16, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded...

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics...

Topics World Trade

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗

September 14, 2026

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

September 14, 2026

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

September 10, 2026

Teva Announces Launch of Offering of Senior Notes

September 07, 2026

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

September 04, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company...

Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗

September 02, 2026

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

September 02, 2026

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

September 01, 2026

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

August 31, 2026

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

August 28, 2026

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

August 19, 2026

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

August 11, 2026

Key innovative brands now generate over $1B quarterly revenue.

Teva (TEVA) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Via The Motley Fool

Topics Earnings

Why Teva Pharmaceutical Stock Surged This Week ↗

August 02, 2026

Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst.

Via The Motley Fool

Topics Stocks

Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗

July 30, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were...